// App-Quantinova.ai

167 : Checkmate 577: Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).

Researchers

Presenter

  • Eric Van Cutsem

Principal Investigators

  • Prianka Singh

  • James M. Cleary

  • Ronan Joseph Kelly

  • Markus H. Moehler

  • Jaroslaw Kuzdzal

  • Guillermo Mendez

  • Satoru Motoyama

  • Elena Elimova

  • Cecile Grootscholten

  • Xiaowu Sun

  • Fiona Taylor

  • Rachael Lawrance

  • Brad Padilla

  • Alejandro Moreno-Koehler

  • Jenny Zhang

  • Steven I. Blum

  • Jaffer A. Ajani

Medical Centers

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Dana-Farber Cancer Institute, Boston, MA

  • The Charles A. Sammons Center at Baylor University Medical Center, Dallas, TX

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

  • Jagiellonian University - John Paul II Hospital, Krakow, Poland

  • Fundacion Favaloro, Buenos Aires, Argentina

  • Akita University, Akita, Japan

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • Adelphi Values, Boston, MA

  • Adelphi Values, Bollington, United Kingdom

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • Belgium

  • United States

  • Germany

  • Poland

  • Argentina

  • Japan

  • Canada

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved